Macroaxis: Personalized Investing
Personalized Investing and
Digital Wealth Optimization

GILD AMGN BIIB CELG Natural Foods Railroads Sport Products 
Benchmark  United States  NYSE  10,582   17.131 Index Moved Down -0.16%  


Processing
Processing. Please wait...

Biogen insider: Gregory Covino

       

Gregory Covino - Biogen Insider Profile

Vice President - Finance

Mr. Gregory F. Covino is Chief Accounting Officer Vice President Finance of Biogen Idec Inc. Prior to that Mr. Covino served at Boston Scientific Corporationrationration a medical device company as Vice President Corporationrationrate Analysis and Control since March 2010 having responsibility for the company internal audit function and as Vice President Finance International from February 2008 to March 2010 having responsibility for the financial activities of the company international division. Prior to that Mr. Covino held several finance positions at Hubbell Incorporated an electrical products company including Vice President Chief Accounting Officer and Controller from 2002 to January 2008 Interim Chief Financial Officer from 2004 to 2005 and Director Corporationrationrate Accounting from 1999 to 2002
Age: 46  President Since 2012      
Gregory Covino Education
Covino received his B.S. in Business Administration from Bryant University.

Management Efficency

The company has return on total asset (ROA) of 14.17 % which means that it generated profit of $14.17 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 23.9 % meaning that it created $23.9 on every $100 dollars invested by stockholders.
The company currently holds 595.93 M in liabilities with Debt to Equity (D/E) ratio of 0.07 which may suggest the company is not taking enough advantage from borrowing. Biogen Idec Inc has Current Ratio of 1.77 which is within standard range for the sector.

Entity Summary

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec Inc [BIIB] is traded on NASDAQ in USA. It is located in Cambridge, MA and employs 6,850 people.

Filter other executives

Specify Title
Indicate Tenure
Select Industry
Click to run this filter
 Run Equity Filter
Filter Other Insiders
 
Showing first 70 of many records found

PRESIDENT Since

Paul SilvaVertex Pharmaceuticals Incorpor
2011
Michael PartridgeVertex Pharmaceuticals Incorpor
N/A
Kevin YoungGilead Sciences Inc
2004
Jim DalyIncyte Corporation
2012
Jeff AjerBioMarin Pharmaceutical Inc
2013
Francis deSouzaIllumina Inc
2014
Thomas DanielCelgene Corporation
2012
Thomas DubinAlexion Pharmaceuticals Inc
2010
Katherine LittrellJazz Pharmaceuticals Public Lim
N/A
Joseph LaRosaRegeneron Pharmaceuticals Inc
2011
Robert LandryRegeneron Pharmaceuticals Inc
2013
Jeffrey CooperBioMarin Pharmaceutical Inc
2012
Fintan KeeganJazz Pharmaceuticals Public Lim
2012
Saqib IslamAlexion Pharmaceuticals Inc
2013
Kirk SchumacherSeattle Genetics Inc
2014
Peter PowchikRegeneron Pharmaceuticals Inc
2006
Matthew PosardIllumina Inc
2012
Roy BaynesGilead Sciences Inc
2012
Charles DadswellIllumina Inc
2013
Michel BouchardIllumina Inc
2013
Sean HarperAmgen Inc
2012
BIIB
Biogen Idec Inc
USA Stock
Currency: USD - US Dollar
Traded on NASDAQ
 

Fix Your Portfolios with Biogen

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Biogen Idec Inc to your portfolio

Promote Biogen and Gregory Covino

Follow Biogen with Macroaxis syndicated feed, custom widget, or your favorite custom stock ticker

Biogen Idec Leadership

Lynn Schenk, Director
Steven Holtzman, President
Paul Clancy, CFO, MBA
Ray Pawlicki, President
John Cox, EVP, MBA
Gregory Covino, President
Robert Pangia, Director
Eric Rowinsky, Director, Ph.D
Caroline Dorsa, Director
Douglas Williams, EVP
Steven DPhil, EVP
Richard Mulligan, Director
Stelios Papadopoulos, Director, Ph.D
George Scangos, CEO, Ph.D
Alexander Denner, Director
Brian Posner, Director
Stephen Sherwin, Director
Susan Alexander, President
Kenneth Pietro, President
Tony Kingsley, President, MBA
William Young, Chairman
Robert Gagnon, President, MBA
Nancy Leaming, Director
Alfred Sandrock, President, Ph.D
Spyros Artavanis-Tsakonas, President, Ph.D
Kenneth DiPietro, EVP
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Find Alpha
Equity Screener
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals, sectors and families
Research Equities
Insiders Screener
Find insiders across different sectors to evaluate their impact on performance and growth of their entities
Research Insiders

Stock Performance

Shares Outstanding236.39 M
Number of Shares Shorted2.98 M